Macrogenics Inc
(NAS:MGNX)
$
4.36
0.25 (6.07%)
Market Cap: 273.08 Mil
Enterprise Value: 122.86 Mil
PE Ratio: 0
PB Ratio: 2.57
GF Score: 60/100 MacroGenics Inc at H.C. Wainwright BioConnect Investor Conference Transcript
May 02, 2023 / 05:00PM GMT
Release Date Price:
$6.81
(-8.10%)
Robert Burns
H.C. Wainwright & Co. - Analyst
Thank you for joining our next fireside chat. I'm Robert Burns as Managing Director and Senior Biotech Analyst at H.C. Wainwright. I'm joined today by Scott Koenig, the CEO of MacroGenics. Scott, thank you for having (multiple speakers) --
Scott Koenig
MacroGenics, Inc. - President, CEO, and Director
It's our pleasure, Robert.
Robert Burns
H.C. Wainwright & Co. - Analyst
So why don't we just dive in? So for those who may be unfamiliar with MacroGenics and its pipeline, can you provide a brief high-level overview of the internal assets that you're developing, as well as what the near-term catalysts look like for MacroGenics?
Scott Koenig
MacroGenics, Inc. - President, CEO, and Director
Thank you very much, Robert. It's been 23 years since the start of the company. So I'm hoping some people are familiar with what we do.
We've been working on immune-based therapeutics, antibody-like structures since our
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot